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Summary
Background: Although Thrombolysis has been
licensed in the UK since 2003, it is still administered
only to a small percentage of eligible patients.
Aim:We consider the impact of investing the impact
of thrombolysis on important acute stroke services,
and the effect on quality of life. The concept is illu-
strated using data from the Northern Ireland Stroke
Service.
Design: Retrospective study.
Methods: We first present results of survival analysis
utilizing length of stay (LOS) for discharge des-
tinations, based on data from the Belfast City
Hospital (BCH). None of these patients actually
received thrombolysis but from those who would
have been eligible, we created two initial groups,
the first representing a scenario where they received
thrombolysis and the second comprising those who
do not receive thrombolysis. On the basis of the
survival analysis, we created several subgroups
based on discharge destination. We then developed
a discrete event simulation (DES) model, where each
group is a patient pathway within the simulation.
Coxian phase type distributions were used to
model the group LOS. Various scenarios were
explored focusing on cost-effectiveness across hos-
pital, community and social services had thromboly-
sis been administered to these patients, and the
possible improvement in quality of life, should the
proportion of patients who are administered thromb-
olysis be increased. Our aim in simulating various
scenarios for this historical group of patients is to
assess what the cost-effectiveness of thrombolysis
would have been under different scenarios; from
this we can infer the likely cost-effectiveness of
future policies.
Results: The cost of thrombolysis is offset by
reduction in hospital, community rehabilitation
and institutional care costs, with a corresponding
improvement in quality of life.
Conclusion: Our model suggests that provision of
thrombolysis would produce moderate overall im-
provement to the service assuming current levels
of funding.
Introduction
Stroke, as the largest cause of disability in the UK, is
of particular concern to policy makers. Within
Northern Ireland (NI), an estimated 4000 people an-
nually suffer a stroke.1 The societal cost of stroke in
the UK is in excess of £8 billion per year of which
direct health-care costs account for approximately
£3 billion.2 Much of the direct care costs are
incurred by community care, including outpatient
care, home-based care packages, community re-
habilitation and institutional care.
Thrombolysis is an effective treatment for ischae-
mic stroke when given in a timely fashion. Although
thrombolytic therapy with intravenous alteplase has
been licensed for use in the UK since 2003, it is only
administered to 3.8% of the stroke patients.3 Stroke
services in the UK are currently being overhauled in
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response to the UK government’s 2007 national
stroke strategy. The strategy has a strong emphasis
on hyper-acute stroke care and on greatly increasing
the proportion of patients being given intravenous
thrombolysis. NI’s stroke strategy targets at least
50% thrombolysis treatment, in those clinically suit-
able, by March 2011. Concerns have been raised
that many other effective components of a compre-
hensive stroke service might not receive as much
attention as a result.4
The aim of this article is to consider if it is bene-
ficial to invest in the provision of thrombolysis in
terms of cost and quality of life. Unique to the UK,
NI has an integrated health and social care board
and is therefore an ideal platform for examining
these issues.
Methods
Our initial data was a 5-year retrospective data set
extracted from the Patient Administration System
(PAS) consisting of patients admitted to the Belfast
City Hospital (BCH) between January 2003 and
December 2007 with a diagnosis of stroke. A total
of 33% (n=655) were diagnosed with cerebral in-
farction, 7.8% (n= 154) with cerebral haemorrhage,
21.4% (n=425) with transient ischaemic attack and
37.8% (n=751) with unspecified stroke. Stroke pa-
tient care in BCH is provided in a combined stroke
unit where the patient is managed by a period of
acute care followed by a period of rehabilitation, if
required, prior to discharge. Such a unit is common
practice in the UK and has been found to reduce
mortality and dependency.5
Our second source of data was a 5-year retro-
spective extract of patients known to us from the
PAS data set who were subsequently discharged
from BCH to the South-East Belfast Community
Stroke Scheme (rehab). From this data set, we
were able to link the records in order to establish
the number of contact hours in the community with
multidisciplinary professionals (physiotherapists, oc-
cupational therapists and speech and language
therapists).
Probability estimates
We analysed data for patients diagnosed with cere-
bral infarction in the PAS data set (n= 655). Within
this group, 64% (n= 419) are included in our simu-
lation having met the NINDS6 criteria for age (4 80
years) and are thus considered to be potentially eli-
gible for thrombolysis.
Discharge dispositions are home, rehab, institu-
tional care (PNH) and death. Probabilities of dis-
charge disposition were estimated from the PAS
data set (Table 1).
Probabilities of discharge disposition for patients
who were notionally administered thrombolysis
were derived from the NINDS trial. The odds ratio
(OR) of a reduction in dependency was OR 0.69
(95% CI 0.50–0.95); therefore, 31% of the patients
who are dependent had a probability of a favourable
outcome. A favourable outcome is defined as
discharge to home (with or without community re-
habilitation) and dependency is defined as discharge
to a PNH.7,8 The probability of patients requiring
community rehabilitation is reduced by 22% for
those patients that are administered thrombolysis.7
Despite a significant increased risk of symptomatic
intracranial haemorrhage within the first 7–10 days,
the NINDS trial found no statistically significant dif-
ference between thrombolysis and placebo in all
cause mortality at 3 months (OR 1.15; 95% CI
0.62–2.16.), therefore probability estimates of
Table 1 Descriptive statistics for patients who are considered as eligible for thrombolysis
Variable N (%) Mean LOS (days) (SD)
Overall LOS 419 33.01 (47.61)
Age (480 years) Average age= 67.8 years
Gender
Male 221 (52.7) 30.38 (49.44)
Female 198 (47.3) 35.94 (45.42)
Destination
Home without Rehab 308 (73.5) 27.43 (43.31)
Home with Rehab 27 (6.4) 46.63 (29.31)
PNH 25 (6.0) 88.16 (63.74)
Death 59 (14.1) 32.56 (59.69)
N: number of patients; SD: standard deviation of LOS.
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death will not be adjusted. Likewise, although there
was an excess of haemorrhage in the treatment
group, and an excess of death (21 vs. 17), there
was a reduction in those requiring the assistance
of others as measured by Modified Rankin 4–6
from 27 to 23, and as measured by Barthel Index
0–50 from 18 to 17. Therefore, although it is a rea-
sonable assumption that the excess of haemorrhage
led to more deaths, there is no support for an as-
sumption that it led to an excess of dependency, and
therefore no evidence of an increase in the numbers
of patients who might need nursing home care.
Since 2008, the BCH has introduced a policy
of increasing thrombolysis where possible.
Information in respect of such patients is recorded
in the SITS-MOST database where adjusted propor-
tions for mortality and independence at 3 months
are comparable with RCT trials.9
Cost estimates
For thrombolytic therapy, we attach a unit cost of
£750 per person in acute care. This figure includes
the cost of the drug as £480 and additional costs
such as staff time.10,11 We note that this cost is con-
sistent with the NHS tariff for thrombolysis used to
pay the hospital. This excludes the organizational
and structural costs of improving stroke services,
such as access to hyper-acute care, that are not
solely attributable to thrombolysis. For in-hospital
bed occupancy we attach costs of £164.80 per
person per day in acute care and £114.80 for
non-acute care.11 For PNH care, we attach a cost
of £81.43 per person per day9 and for community
rehabilitation we attach a cost of £38 per person per
hour of client contact.12 All costs are based on UK
figures.
Estimates for in-hospital and community
length of stay
Length of stay (LOS) in hospital is derived from the
PAS data set. For patients who are thrombolysed
LOS in acute care is assumed to be reduced by
2 days.6 Number of hours of community rehabilita-
tion is estimated from data of stroke patients dis-
charged to rehab. We assume that this figure is not
altered as a consequence of thrombolysis. LOS in a
PNH is estimated to be 11.9 months (median figure
for mortality).13 Discharge from institutional care is
predominately by death; therefore, we use mortality
as an estimate of LOS in a PNH. While a minority of
people are readmitted to hospital from institutional
care this usually means terminal care.14
Health outcomes
The health outcome measure used in the model is
the quality-adjusted life year (QALY), an arithmetic
product of life expectancy and quality of life in a
health state during that time. Our simulation
model focuses on three health states (death, survival
in an independent state or survival in a dependent
state) and we assign utility values of 0, 0.71 and
0.32 respectively.15 Judgements made in regard to
life expectancy following thrombolysis were compli-
ant with NINDS recommendations. QALYS were
discounted by 3.5%, the rate recommended for eco-
nomic evaluations in the UK.16
Sensitivity analysis
Within the current economic climate health-care
costs are subject to a certain degree of uncertainty.
To test the robustness of the model to any increase
in costs, univariate sensitivity analyses were per-
formed on costs of thrombolysis, community re-
habilitation, PNH and daily costs of in-hospital
stay. The effect of varying the cost of each parameter
was examined by varying estimates in increasing
increments of 5% (from 0% to 30%). Baseline
costs were fixed assuming 20% of patients were ad-
ministered thrombolysis.
Probabilistic sensitivity analysis (PSA) was
carried out by simultaneously varying all five costs
and the QALY using the lognormal and normal
distribution, respectively. The 95% confidence
intervals were £580.15–£954.66 (thrombolysis),
£127.48–£209.77 (acute), £88.80–£146.13
(long-stay), £22927.59–£37728.07 (PNH) and
£764.25–£1257.60 (rehabilitation). For QALYs, the
equivalent ranges were 3.28–9.85 (home) and
1.48–4.44 (PNH).
Survival analysis
Classical survival analysis was used to cluster LOS
data and generate homogeneous groups. Age was
not included as a covariate in the current analysis
as the current licence for thrombolysis in the UK
only permits patients who are 480 years to be ad-
ministered the drug.
It is well documented that women fare worse than
men following acute ischaemic stroke. However,
gender-related clinical prognosis in response to
thrombolysis is debatable.17 Kaplan–Meier estima-
tion and log-rank tests were performed to examine
the relationship between gender and LOS in hospital
for those considered eligible for thrombolysis. The
log-rank test for the equality of survival distributions
showed no significant relationship (2 statistic 2.10,
P>0.05) between LOS and gender. Therefore
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gender was not included as a covariate within the
simulation.
Kaplan–Meier estimation and log-rank tests were
performed to examine the relationship between LOS
in hospital and discharge destination for those pa-
tients considered eligible for thrombolysis. The
log-rank test showed a significant relationship
(2 statistic 29.22, P=0.000) between LOS and dis-
charge destination, with the survival plot given in
Figure 1.
The simulation model
We created two initial groups—T (patients that no-
tionally were thrombolysed) and NT (patients that
were not thrombolysed). Based on the survival ana-
lysis, six subgroups were created from T and NT to
accommodate the different destinations (home, PNH
and death). Two further subgroups were created
from the T and NT home groups, to accommodate
the proportion of patients who were discharged
home with rehab (Figure 2).
The groups were then used to develop a discrete
event simulation (DES) model, using the software
package SIMUL8, where each group represents a
patient pathway within the simulation. DES is a
computer modelling method that permits entities
(e.g. patients) within a system to interact and/or
compete with each other for resources. It is a par-
ticularly suitable approach for complex systems,
such as the health service, where multiple variables
may produce an enormous number of possible
connections and effects.18 In each case the Coxian
phase type distribution was used to model the group
LOS. Phase type models are a popular choice to fit
LOS data within the health-care sector and have
previously been shown to give a good fit.19–21
Coxian phase type distributions are intuitively ap-
pealing as we can think of the patient progressing
through various phases of care, such as assessment,
treatment and rehabilitation. Using a penalized
maximum likelihood approach,22 phase type distri-
butions were fitted to each group starting in each
case, with one phase (exponential) and progres-
sively increasing the number of phases until an op-
timal number of phases were determined to estimate
a true model. The goodness-of-fit of these phase-
type LOS distributions was previously tested for
each subgroup using both a Kolmogorov–Smirnov
test and a chi-squared test and shown to be
reasonable.22
Mean duration of LOS in hospital was estimated
separately for each of the three destinations—home,
PNH and death (Table 1). The transition rates in
each case were estimated using maximum likeli-
hood estimation. In Table 2 and Figure 3, we present
percentile of LOS in hospital for patients who are
thrombolysed and not thrombolysed and those dis-
charged to home, PNH and death respectively.
Those who are discharged home and those who
die in hospital have similar profiles while those dis-
charged to a PNH tend to have much longer LOS in
hospital. Also those who are thrombolysed have
slightly shorter LOS than those who are not.
We tested various scenarios by adjusting the pro-
portion of eligible patients receiving thrombolysis.
The simulation was carried out for a time period of
6000 days (3000 days warm up period) and was
replicated 10 000 times with the same random
number streams to ensure accuracy of our results.
The model was validated by comparing observed
figures for LOS by discharge disposition from the
PAS data and estimated figures from our simulation
model (Table 3).
Results
Our model suggests that the total overall cost of
treating 50% of eligible patients in NI with thromb-
olysis, instead of standard therapy, could decrease
from £6355 to £6243 per appropriate patient.
Increasing the provision of thrombolysis from 10%
to 50% of eligible patients can potentially result in
monetary savings of 8.26% in community rehabili-
tation costs and 12.3% in institutional care per
person eligible for thrombolysis (Figure 4a and b).
The breakdown of expected cost for thrombolysis,
acute care, long-stay care, rehabilitation and PNH
for 10% and 50% thrombolysis, respectively, is pre-
sented in Table 4 where we can see that the
increased cost of thrombolysis is more than
Figure 1. Kaplan–Meier destination distributions on sur-
vival times.
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compensated for by a decrease in cost of long-stay
patients; there is also a small decrease in costs of
rehabilitation and PNH when thrombolysis in-
creases. Table 4 also presents the percentage of
patients who require long-stay hospital care, com-
munity rehabilitation and PNH care, respectively.
Approximately, 33% of the patients require
long-stay care, whereas 5 or 6% of the patients re-
ceive each of community rehabilitation and PNH
care.
Sensitivity analysis
The parameters most sensitive to change were daily
costs for in-hospital stay at acute and non-acute
phases (Figure 4c). Results of the sensitivity analysis
suggest that even if there were a 30% increase in
daily costs in hospital, thrombolytic therapy would
remain acceptable value for money. From the PSA,
we found that 95.9% of the time, 50% thrombolysis
of eligible patients was cheaper than 10%
thrombolysis.
Cost-effectiveness—the QALY
Our model suggests that the average number of
QALYs per potentially clinicially appropriate patient
could increase from 5.442 to 5.475—a gain of
0.033, or 12 days of life (Figure 4d). From the
PSA, 50% thrombolysis of eligible patients had
higher QALYs 97.8% of the time than with 10%
thrombolysis.
Figure 2. The simulation model.
Table 2 Percentiles for LOS (days) in hospital for each patient class
Discharge Destination 0.15 0.25 0.50 0.75 0.95
Thrombolysed and Discharged Home 0.8 4.6 12.2 30.9 108.3
Thrombolysed and Discharged to PNH 11.9 39.6 73.0 120.4 216.2
Thrombolysed and Died 0.9 5.3 13.5 32.5 141.4
Not thrombolysis and discharged home 0.9 5.5 14.3 34.7 110.9
Not thrombolysis and discharged to PNH 11.9 39.6 73.0 120.4 216.2
Not thrombolysis and died 0.9 5.3 13.5 32.5 141.4
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Discussion
To our knowledge, this is the first (UK) study to have
modelled the cost-effectiveness that can be
achieved by increasing the provision of thromboly-
sis to appropriate patients within a stroke service.
Previous modelling exercises have focused on the
provision of t-pa vs. non-t-pa and have in the main
have been based on empirical data from the NINDS
trial. A major strength of this article is that in NI we
have a unique integrated health and community
social services; therefore, we were able to extract
the full patient pathway. Unique to cost-
effectiveness research, we were able to establish
the actual average cost per person for community
rehabilitation from our analysis of the South East
Belfast Community Stroke Scheme data set.
However, potential weakness of this article is that
we did not include costs for home-based care pack-
ages. This would have been difficult to estimate as
the intensity of care packages vary considerably
with regard to the needs of the patient, family sup-
port networks and the availability of financial
resources among different health-care trusts.
However, if we had included these costs it would
not have increased the costs of non thrombolysed
patients relative to thrombolysed patients but might
have introduced more variance. We also assumed
that that the period of rehabilitation required would
be unchanged as a result of thrombolysis. Again this
would have been difficult to estimate, although if
thrombolysis does reduce the intensity of rehabilita-
tion required in the community this would be likely
to further reduce costs.
Where the diagnosis was coded as unspecified
stroke within the PAS database, we apportioned pa-
tients to either cerebral infarction or cerebral haem-
orrhage by checking the BCH stroke unit records.
These apportioned cerebral infarction patients
were included in the thrombolysis model, along
with those recorded as cerebral infarction in the
PAS data set.
Our model suggests that the initial expenses of
thrombolysis can be offset by the savings made
within the hospital setting, community rehabilitation
and institutional care. Within a NI context, we esti-
mate an annual saving of approximately £35 000
should the provision of thrombolysis be increased
from 10% to 50% of eligible patients. We estimate
potential financial savings of 8.25% in community
rehabilitation should the provision of thrombolysis
be increased to 50%. Initial analysis of the PAS data
indicates that patients who require community re-
habilitation or institutional care spend a consider-
ably long time in hospital. Prolonged LOS is
considered an inefficient use of resources and has
long presented a challenge for health-care managers
and policy makers. Our model suggests that
Figure 3. Percentiles of LOS in hospital for different classes of patients.
Table 3 Validation of simulation model
Discharge
Destination
Observed from
PAS data
Estimated from
simulation model
Home 27.43 (43.3)a 28.85 (39.82)
PNH 88.16 (63.74) 88.25 (65.59)
Death 32.56 (59.69) 32.43 (54.65)
aLOS, mean (SD).
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increasing the provision of thrombolysis should
reduce the requirement for institutional care. This
will be welcome news for policy makers as it is
estimated that 25% of the post stroke patients in
the UK enter institutional care.23 With regard to
the initial expense of thrombolysis, Actilyse is cur-
rently the only drug indicated for thrombolytic treat-
ment of patients with ischemic stroke in the UK.
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Figure 4. (a) Savings in rehab costs per person that is eligible for thrombolysis. (b) Savings in PNH costs per person that is
eligible for thrombolysis. (c) Sensitivity analysis. Effects of percentage increase of cost of each parameter on total cost per
person that is eligible for thrombolysis (based on a figure of 20% of the patients treated). (d) Increase in QALYs per person
that is eligible for thrombolysis.
Table 4 Expected costs (£) and percentage of patients entering different parts of the system
Percentage The expected
cost of
thrombolysis
The expected
cost in
acute care
The expected
cost in
long-stay care
The expected cost
when discharged
home with rehab
The expected cost
when discharged
to PNH
Total
10% 74.99981 2364.896 2114.142 62.7142 1716.645 6333.397
50% 375.0082 2215.647 2092.342 57.55916 1503.31 6243.865
Cost decrease 300.008 149.2494 21.80007 5.155032 213.3355 89.53167
Percentage
receiving
thrombolysis
Percentage
receiving
acute care
Percentage
receiving
long-stay care
Percentage
discharged
home with rehab
Percentage
discharged
to PNH
10% 10.0 100.0 33.9 6.3 5.8
50% 50.0 100.0 33.5 5.8 5.1
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We have modelled an increase in the provision
of thrombolysis from 10% to 50% of patients who
are considered as eligible for thrombolytic therapy
(under the current licensing arrangements).
Although there is a theoretical ceiling as to the pro-
portion of these patients who might benefit from, or
be clinically appropriate for such therapy, it has
been suggested that the number of eligible patients
excluded on the basis of clinical factors, such as
hypertension and use of anti-coagulants, to be rela-
tively small.24 Time to presentation will exclude
many subjects given the 3-h treatment window of
the current license. Applying this restriction to the
existing license criteria, figures from the 2008
National Sentinel Stroke Audit suggested that
about 15% of the unselected stroke admissions
would be suitable for treatment with alteplase. Our
figure of 50% of the patients who are considered as
eligible for thrombolytic therapy translates to 26% of
the unselected strokes. Increasing the time window
for thrombolysis up to 4.5 h and on-going public
awareness campaigns promoting earlier presenta-
tion should make our theoretical ceiling achievable.
The health outcome measure used in the model is
the QALY. Consistent with previous models,7,8,10
our results suggest that an increase in the provision
of thrombolysis could result in an increased number
of QALYs per eligible patient. Within a NI context,
we estimate an annual gain of approximately 13
QALYs should the provision of thrombolysis be
increased to 50% of patients that are clinically
appropriate.
Conclusions
We conclude that, if current levels of funding are
maintained, increased provision of thrombolysis
should produce moderate financial savings for the
NI stroke service alongside an increase in patient
quality of life.
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